Last reviewed · How we verify
GM102 expansion — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
GM102 expansion (GM102 expansion) — GamaMabs Pharma.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GM102 expansion TARGET | GM102 expansion | GamaMabs Pharma | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GM102 expansion CI watch — RSS
- GM102 expansion CI watch — Atom
- GM102 expansion CI watch — JSON
- GM102 expansion alone — RSS
Cite this brief
Drug Landscape (2026). GM102 expansion — Competitive Intelligence Brief. https://druglandscape.com/ci/gm102-expansion. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing